Combatting Chikungunya: Valneva's Chikungunya Vaccine Cleared by USFDA, Eyes India Launch

▴ Chikungunya Vaccine
As Valneva works towards making this groundbreaking vaccine available in India, the collaboration with CEPI and Instituto Butantan underlines the global effort to address infectious diseases. The upcoming regulatory interactions with DCGI will shed light on the timeline for Ixchiq's launch in India.

In a significant stride against the mosquito-borne illness chikungunya, French biotech company Valneva has secured approval from the US Food and Drug Administration (USFDA) for its vaccine, Ixchiq. This marks a groundbreaking moment as it becomes the first licensed vaccine globally to combat this viral disease. The company now sets its sights on making this innovative vaccine available in India, with plans to collaborate with the Coalition for Epidemic Preparedness Innovations (CEPI) and Instituto Butantan in Brazil.

Ixchiq Approval and Global Impact: The USFDA's recent approval of Ixchiq targets individuals aged 18 and above at an increased risk of exposure to the chikungunya virus. This virus, primarily transmitted by the Aedes mosquito, poses a global health threat, with at least 5 million reported cases globally in the past 15 years. The disease, characterized by severe arthritis, fever, and rash, though rarely life-threatening, is debilitating and challenging to treat.

Valneva's Commitment to Accessibility: In response to inquiries about the vaccine's availability in India, Valneva's Chief Medical Officer, Juan Carlos Jaramillo, expressed the company's commitment to making Ixchiq accessible in the country. Through partnerships with CEPI and Instituto Butantan, an agreement signed in January 2021, the aim is to extend the availability of the chikungunya vaccine to low- and middle-income countries. However, specific details about the vaccine's distribution in India, whether through the government's Universal Immunization Programme or the private market, are yet to be finalized.

Regulatory Processes and Timelines: Jaramillo emphasized that the timeline for introducing Ixchiq in India would be determined after regulatory interactions with the Drugs Controller General of India (DCGI). While the company is diligently working with partners, decisions regarding distribution channels will factor in regulatory timelines and requirements.

Chikungunya in India: Chikungunya's resurgence in India in 2006 and its subsequent impact on public health have been notable. Data from the National Center for Vector Borne Diseases Control (NCVBDC) under the Union Health Ministry highlights a substantial number of suspected and confirmed cases since 2018. In 2022 alone, there were 1,48,587 suspected and 8,067 confirmed cases across the country.

The USFDA approval of Valneva's Ixchiq heralds a new chapter in the fight against chikungunya, offering hope for those at risk. As Valneva works towards making this groundbreaking vaccine available in India, the collaboration with CEPI and Instituto Butantan underlines the global effort to address infectious diseases. The upcoming regulatory interactions with DCGI will shed light on the timeline for Ixchiq's launch in India, marking a significant step in strengthening the nation's defences against chikungunya

Tags : #chikungunya #vaccine #USFDA #Valneva #CEPI #mosquitoborne #viralillness #medicircle

About the Author


Sunny Parayan

Hey there! I'm Sunny, a passionate writer with a strong interest in the healthcare domain! When I'm not typing on my keyboard, I watch shows and listen to music. I hope that through my work, I can make a positive impact on people's lives by helping them live happier and healthier.

View Profile

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Budget 2024- 25’s Healthcare Push: Real Reform or Just Another Election Strategy?February 03, 2025
FedEx Remains Highest Ranked Delivery Company on Fortune’s “World’s Most Admired Companies” Overall List February 03, 2025
FedEx Remains Highest Ranked Delivery Company on Fortune’s “World’s Most Admired Companies” Overall List February 03, 2025
Amrita Vishwa Vidyapeetham To Host A Three-Day International Conference on "Synergizing Eco Interventions for Achieving SDGs”January 31, 2025
Cotecna Life Sciences India Inaugurates New Laboratory in MumbaiJanuary 31, 2025
Senior Citizens vs. Insurance Giants: IRDAI Puts an End to Exploitative Premium HikesJanuary 31, 2025
Two Deaths, 130 Cases: Is Contaminated Water Fuelling the Guillain-Barre Surge in Maharashtra?January 31, 2025
Wellbeing Nutrition ropes in Sharvari as the brand ambassador to simplify nutrition January 30, 2025
58,000 Lives Lost Every Year: Why Snakebite Victims in India Are Dying NeedlesslyJanuary 30, 2025
Three Deaths, One Rare Disease: Is West Bengal Facing an Undetected Health Crisis?January 30, 2025
The Silent Monthly Struggle: How Periods Are Still Holding Women BackJanuary 30, 2025
Dr. Pooja Chopra - Consultant Dermatology - Aakash Healthcare, New Delhi Leprosy Day and Public Health: Promoting Early Diagnosis and Support for Affected CommunitiesJanuary 30, 2025
Moscow scientists have developed 11 medical phantoms to enhance Patient DiagnosisJanuary 29, 2025
Using AI to Predict the Outcome of Aggressive Skin CancersJanuary 29, 2025
A Baby Within a Baby: Doctors Stunned as Maharashtra Woman’s Baby Is Found Carrying a TwinJanuary 29, 2025
Ageing with Dignity: The Multi-Crore Investment in Geri Care That would Change Elderly Care ForeverJanuary 29, 2025
Revolutionizing Healthcare at Maha Kumbh Mela 2025: Lifesigns and AIIMS Transform Patient Monitoring with Advanced TechnologyJanuary 29, 2025
Is AI Making Us Less Intelligent? The Hidden Cost of ConvenienceJanuary 28, 2025
The Biotech Startup Giving Chemotherapy a New Lease on LifeJanuary 28, 2025
Guillain-Barré Syndrome: Experts Recommend Early Detection and Advanced Care Amid Rising CasesJanuary 28, 2025